Your Scarred Liver Is Already Fighting Back. Scientists Have Just Figured Out How

The liver is, in most respects, forgiving. Damage it repeatedly with alcohol, or hepatitis, or bile that can’t drain, and it will scar. It will tighten and stiffen and lose its architecture over years of insult, eventually becoming the cirrhotic, shrunken organ that kills roughly two million people every year. But it does not simply surrender. Buried within the scar tissue, a protein called cathepsin K has been quietly accumulating, rising in lockstep with the damage, as if the liver were mounting its own internal resistance. Researchers at Hebei Medical University in China have now worked out what that protein is actually doing. And the answer is stranger, and more useful, than anyone expected.

Cathepsin K has a reputation. It is, in the popular biochemical imagination, a destructive enzyme: a cysteine protease best known for its role in osteoclasts, the cells that dissolve bone. Drug companies have spent billions trying to inhibit it in patients with osteoporosis and rheumatoid arthritis. The idea that the same molecule might be protecting a diseased liver rather than making things worse was not, perhaps, the first hypothesis anyone would have reached for.

The study, published in the Journal of Clinical and Translational Hepatology in January, began with an observation in human liver biopsies. Across three independent patient cohorts, spanning hepatitis B, hepatitis C, and alcohol-related liver disease, cathepsin K levels tracked fibrosis severity. The more advanced the scarring, the more of the enzyme was present. That correlation could mean two very different things: cathepsin K might be driving the damage, or it might be responding to it. Distinguishing between those possibilities took rather more work than simply plotting a graph.

The Cells That Build the Scars

To understand what the protein is doing, you need to understand the cells it’s working in. Liver fibrosis is not really a disease of liver cells. It’s a disease of hepatic stellate cells, a population of quiescent, vitamin A-storing cells scattered through the organ that, under chronic stress, transform into something quite different. They become activated, proliferative, and fanatically committed to producing collagen. It is this shift, from sleepy maintenance cells to fibre-producing myofibroblasts, that generates the scar tissue. And it is orchestrated almost entirely by a single molecular conductor: transforming growth factor-beta, or TGF-beta, one of the most pleiotropic signalling molecules in the human body.

Targeting TGF-beta directly has proved, to put it gently, fraught. The molecule is involved in immune surveillance, wound healing, embryonic development, and about four dozen other processes that you would prefer to leave undisturbed. Blocking it systemically tends to cause more problems than it solves. What researchers have been hunting for, for decades, is something more precise, a way of interrupting the fibrosis signal without touching everything else TGF-beta does. Cathepsin K, it turns out, may have evolved something rather close to that solution already.

The Hebei team found that when TGF-beta activates a hepatic stellate cell, the cell responds by upregulating cathepsin K in a time-dependent manner. The more TGF-beta pushes, the more cathepsin K accumulates. And cathepsin K, in turn, dismantles one of the key components of TGF-beta’s own signalling machinery: the receptor through which TGF-beta talks to the cell in the first place.

Taking Out the Antenna

TGF-beta signals through a pair of cell-surface receptors, type I and type II. The type I receptor does most of the downstream work, activating Smad proteins that migrate to the nucleus and switch on collagen-producing genes. Cathepsin K does not block TGF-beta directly; instead, it degrades the type I receptor, essentially dismantling the antenna before the signal can be relayed. When the researchers treated cells with a proteasome inhibitor, the degradation stopped entirely, confirming that cathepsin K routes the receptor through the cell’s standard protein-disposal machinery. The mRNA encoding the receptor was unaffected throughout. Post-translational regulation of unusual elegance, roughly analogous to pulling the plug from the wall rather than arguing with whatever is playing on television.

The process depends on two other proteins, Smad7 and Smurf2, which form a well-characterised complex that tags proteins for disposal. Cathepsin K upregulates Smad7, which then mobilises Smurf2 from the cell nucleus into the cytoplasm, where it can attach to the type I receptor and mark it for degradation. Knock out Smad7, and the whole cascade falls apart: the receptor survives, TGF-beta signalling continues unimpeded, and cathepsin K’s protective effect evaporates. The authors ran those knockdown experiments carefully, and the results were consistent. This is a genuine feedback loop, not a coincidental correlation.

There is a second mechanism running in parallel, and it seems to operate independently. Cathepsin K also shifts the balance of apoptotic proteins inside hepatic stellate cells, increasing Bax (which promotes cell death) and decreasing Bcl-2 (which prevents it), with downstream activation of caspase-3. Activated stellate cells are notoriously resistant to apoptosis, which is one reason fibrosis is so difficult to reverse once established. Cathepsin K appears to crack that resistance open. Critically, when the researchers blocked TGF-beta signalling via Smad7 knockdown, the apoptotic effect persisted unchanged, which means cathepsin K is simultaneously working two levers that do not depend on each other.

Mice, Viruses, and the Translation Problem

Mouse experiments are where liver fibrosis research tends to get interesting and then stall. The team used two standard models, one involving repeated carbon tetrachloride injections to simulate toxic injury, and one involving bile duct ligation to mimic cholestatic disease. They delivered extra cathepsin K to the liver using an adeno-associated virus (AAV8), a gene therapy vector with a particular fondness for liver tissue. In both models, the results looked encouraging: less collagen deposition on histology, lower serum markers of liver injury, reduced levels of TGF-beta1 and the inflammatory cytokine IL-6, and clear signs of increased stellate cell apoptosis in the fibrotic tissue.

The caveats matter, and the authors are honest about them. AAV8 does not target only stellate cells; it distributes through multiple liver cell types, so the results cannot confirm that everything observed was happening specifically in stellate cells. There is also the precedent from pulmonary fibrosis research, where cathepsin K turns out to have a dual personality: in early-stage lung fibrosis it degrades collagen and helps; in later stages it promotes fibroblast metabolism in ways that worsen things. Whether something similar could happen in the liver with prolonged overexpression is unknown.

There is also the question of what happens to patients who are already taking cathepsin K inhibitors for osteoporosis. The drug odanacatib was developed precisely to suppress this enzyme in bone, and though it was eventually abandoned for cardiac reasons, several related compounds remain in clinical development. The new findings suggest that systemic cathepsin K inhibition, if it were broadly adopted, could potentially leave the liver more vulnerable to fibrosis by removing a protective brake. That is a speculative concern at this stage, not a demonstrated risk, but it is the kind of concern that tends to get more interesting as drug development advances.

What the research does establish, fairly convincingly, is that cathepsin K upregulation in fibrotic liver is not a passive bystander phenomenon or a marker of damage. It is an active, mechanistically coherent response that partially counteracts the very process generating it. The liver, in other words, is already doing something sensible. The challenge now is figuring out how to help it do more of it, precisely, without disturbing the dozen other things this particular enzyme is busy with elsewhere in the body.

Source: doi.org/10.14218/JCTH.2025.00592

Frequently Asked Questions

If cathepsin K is already rising in fibrotic livers, why doesn’t the body heal itself?

The endogenous rise in cathepsin K is real, but it’s not sufficient to override the fibrotic drive, particularly in chronic disease where the original injury keeps repeating. Think of it less as a cure the body is attempting and more as a partial brake on an accelerating process. The new research suggests that amplifying this response artificially, through gene delivery in mice, produces a meaningful anti-fibrotic effect, which is why scientists are interested in it as a therapeutic target rather than just a biomarker.

Could drugs that block cathepsin K for osteoporosis make liver disease worse?

That’s a legitimate concern raised by the research, though it remains speculative at this stage. The study’s findings imply that cathepsin K acts as a protective factor in the liver, so systemic inhibition of the enzyme could theoretically remove that protection. Whether this translates into a clinically detectable worsening of liver fibrosis in patients taking such drugs is something that would need dedicated investigation.

Why is TGF-beta so hard to target as a treatment for liver fibrosis?

TGF-beta is involved in an enormous number of normal biological processes, including immune regulation and wound healing, so blocking it broadly tends to cause collateral damage. What makes the cathepsin K mechanism interesting is that it targets only the type I TGF-beta receptor in activated stellate cells, leaving the rest of the signalling landscape intact. That specificity is exactly what drug developers have been trying to engineer.

Is liver fibrosis actually reversible once it’s established?

In some circumstances, yes. Research over the past decade has shifted the view that cirrhosis is inevitably a one-way process; remove the cause of injury and some degree of regression is possible. The real barrier is the persistence of activated stellate cells, which resist apoptosis even when the original insult has stopped. Cathepsin K’s ability to push those cells toward cell death is, in part, why the research is attracting attention beyond the mechanistic novelty of the signalling story.